Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma

Author： Mallick Rajiv   Cai Jennifer   Wogen Jenifer  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.29, Iss.12, 2013-12, pp. : 1701-1708

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 6, 2010-06 ,pp. : 1023-1025

John Wiley & Sons Inc

Access to resources Recommend Favorite

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 784-791

John Wiley & Sons Inc

Access to resources Recommend Favorite

Oral Doxifluridine in Advanced Hepatocellular Carcinoma: A Phase II Study

By  

Oncology, Vol. 59, Iss. 3, 2000-10 ,pp. : 204-209

Karger

Access to resources Recommend Favorite

Do patients initiate therapy? Primary non‐adherence to statins and antidepressants in Iceland

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 5, 2015-05 ,pp. : 597-603

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination Therapy with S-1 and Pegylated Interferon Alpha for Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 75, Iss. 1, 2008-12 ,pp. : 106-113

Karger

Access to resources Recommend Favorite